Kamada (NASDAQ:KMDA – Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Kamada to announce earnings of $0.13 per share and revenue of $52.51 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.
Kamada (NASDAQ:KMDA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.05. The firm had revenue of $54.92 million for the quarter, compared to analysts’ expectations of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%. On average, analysts expect Kamada to post $0.48 EPS for the current fiscal year and $0.58 EPS for the next fiscal year.
Kamada Price Performance
NASDAQ KMDA opened at $7.70 on Monday. Kamada has a 12-month low of $6.55 and a 12-month high of $9.35. The firm has a 50-day moving average price of $8.19 and a two-hundred day moving average price of $8.02. The company has a market capitalization of $442.83 million, a P/E ratio of 20.26, a P/E/G ratio of 0.65 and a beta of 0.90.
Kamada Cuts Dividend
The firm also recently announced an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were given a $0.17 dividend. This is a drop from Kamada’s previous annual dividend of $0.25. This represents a yield of 206.0%. The ex-dividend date was Thursday, August 27th. Kamada’s dividend payout ratio (DPR) is presently 34.21%.
Wall Street Analyst Weigh In
Several research firms recently commented on KMDA. Weiss Ratings upgraded shares of Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 9th. William Blair set a $15.00 price objective on Kamada in a report on Tuesday, July 21st. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. UBS Group reaffirmed a “buy” rating and set a $15.00 target price on shares of Kamada in a report on Friday, September 18th. Finally, Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $13.50.
Read Our Latest Research Report on Kamada
Kamada Company Profile
Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.
Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.
Featured Stories
- Five stocks we like better than Kamada
- Uranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
